US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.03

+0.09000.75%

Pre-market: 12.030.00000.00%07:38 EDT

Volume:325.87K

Turnover:3.91M

Market Cap:664.71M

PE:10.19

High:12.03

Open:11.96

Low:11.94

Close:11.94

52wk High:13.59

52wk Low:11.82

Shares:55.25M

Float Shares:55.25M

Volume Ratio:0.89

T/O Rate:0.59%

Dividend:1.42

Dividend Rate:11.77%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.83

PE(LYR):- -

Loading ...

Overview Company News Filings

SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044

Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

Brookfield Real Assets Income Fund names Oaktree’s Aaron Greenberg to run securitized credit allocation

Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?

Simply Wall St.

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail

MT Newswires Live

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84

Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/RA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.03,"timestamp":1789675200000,"preClose":11.94,"halted":0,"volume":325873,"hourTrading":{"tag":"盘前","latestPrice":12.03,"preClose":12.03,"latestTime":"07:38 EDT","volume":7,"amount":84.21,"timestamp":1789731481865,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.007537688442211044,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Pre-Mkt","change":0.09,"latestTime":"09-18 08:15:04 EDT","open":11.96,"high":12.03,"low":11.94,"amount":3905789.620387,"amplitude":0.007538,"askPrice":12.99,"askSize":5600,"bidPrice":11.07,"bidSize":6100,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.03,"dividendRate":0.117747,"preHourTrading":{"tag":"盘前","latestPrice":12.03,"preClose":12.03,"latestTime":"07:38 EDT","volume":7,"amount":84.21,"timestamp":1789731481865,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.03,"preClose":12.03,"latestTime":"19:30 EDT","volume":52,"amount":637.28,"timestamp":1789687808628,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8888727043735645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8888727043735645,"shares":55254696,"dividePrice":1.4165,"high":12.03,"amplitude":0.007538,"preClose":11.94,"low":11.94,"week52Low":11.82,"pbRate":"0.83","week52High":13.59,"institutionHeld":0,"latestPrice":12.03,"committee":0.042735,"eps":1.18,"divideRate":0.117747,"volume":325873,"delay":0,"ttmEps":1.18,"open":11.96,"prevYearClose":12.96,"prevWeekClose":12.18,"prevMonthClose":12.55,"prevQuarterClose":12.88,"fiveDayClose":12.21,"twentyDayClose":12.62,"sixtyDayClose":12.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643222675","title":"SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2643222675","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643222675?lang=en_us&edition=fundamental","pubTime":"2026-06-15 13:02","pubTimestamp":1781499779,"startTime":"0","endTime":"0","summary":"SynAct Pharma AB ( ($SE:SYNACT) ) has shared an update. SynAct Pharma reported Phase 2b ADVANCE trial data showing that its oral candidate resomela...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/synacts-ra-drug-resomelagon-delivers-positive-phase-2b-data-fuels-partnering-push?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/synacts-ra-drug-resomelagon-delivers-positive-phase-2b-data-fuels-partnering-push?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU2238330802.EUR","IE0031814969.USD","SG9999002620.SGD","LU0345776255.USD","LU1048588211.SGD","LU0345775950.USD","SG9999004360.SGD","LU2152927971.USD","BK4085","SG9999002679.SGD","LU2008162690.USD","LU0516422440.USD","LU0823039010.USD","BK4551","LU0737861269.HKD","LU2065171402.SGD","LU0516422366.SGD","LU0516423174.USD","LU1861217088.USD","LU1242518857.USD","BK4535","SG9999001135.SGD","LU2065169927.USD","SG9999014492.USD","SGXZ58947870.SGD","SG9999013486.USD","IE00BD6J9T35.USD","LU2125910849.SGD","SG9999006266.SGD","IE0034224299.USD","LU0823038988.USD","LU0516422952.EUR","LU0264606111.USD","LU0251143029.SGD","LU0572939691.SGD","LU0589944569.HKD","LU2045819591.USD","LU0979878070.USD","LU1242518931.SGD","LU0175139822.USD","LU2177674079.SGD","BK4548","LU1839390173.USD","LU0499858602.USD","LU0441851309.USD","LU1770036033.HKD","SG9999013460.SGD","LU2360107671.USD","LU0210637038.USD","BK4220","SG9999013478.USD","SG9999002604.SGD","BK4503","BK4566","SG9999005177.SGD","BK4554","LU0348788117.USD","LU0499858438.USD","SG9999014484.SGD","BK4588","LU0532188223.SGD","RA","LU2065171311.SGD","LU2543165471.USD","LU2125910500.SGD","LU0072462343.USD","LU2065170008.USD","SG9999002406.SGD","LU1861220207.SGD","SE","SG9999002414.USD","LU0048573645.USD","LU0289960550.SGD","LU0572940350.SGD","BK4585","LU0261945553.USD","LU0516423091.SGD","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643214376","title":"FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2643214376","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643214376?lang=en_us&edition=fundamental","pubTime":"2026-06-13 17:39","pubTimestamp":1781343540,"startTime":"0","endTime":"0","summary":"WUHU, China, June  13, 2026  (GLOBE NEWSWIRE) -- In a significant milestone for the global premium new energy vehicle industry, FREELANDER 8 made its first public appearance at the Abu Dhabi Investmen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/13/3311375/0/en/FREELANDER-8-Makes-First-Public-Appearance-Ahead-of-Official-Abu-Dhabi-Launch.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642919682","title":"SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044","url":"https://stock-news.laohu8.com/highlight/detail?id=2642919682","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642919682?lang=en_us&edition=fundamental","pubTime":"2026-06-12 23:37","pubTimestamp":1781278629,"startTime":"0","endTime":"0","summary":"SynAct Pharma AB ( ($SE:SYNACT) ) has shared an announcement. SynAct Pharma AB has secured a key U.S. patent for its lead candidate resomelagon (AP...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/synact-extends-u-s-patent-exclusivity-for-lead-ra-therapy-resomelagon-to-2044?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/synact-extends-u-s-patent-exclusivity-for-lead-ra-therapy-resomelagon-to-2044?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0048573645.USD","SG9999013486.USD","LU0823038988.USD","LU2065171402.SGD","LU0210637038.USD","SE","LU0737861269.HKD","IE00BD6J9T35.USD","LU0572940350.SGD","LU1048588211.SGD","LU0499858602.USD","LU2125910500.SGD","BK4535","LU2065171311.SGD","LU0823039010.USD","IE0034224299.USD","LU0072462343.USD","SG9999006266.SGD","BK4554","LU0516423091.SGD","LU1242518931.SGD","IE0001KFT4U8.USD","BK4581","LU0289960550.SGD","LU0499858438.USD","BK4566","BK4220","LU2543165471.USD","SGXZ58947870.SGD","LU1861220207.SGD","BK4503","BK4585","SG9999013478.USD","LU0516423174.USD","LU0345776255.USD","BK4588","LU2360107671.USD","LU1839390173.USD","LU2065170008.USD","BK4085","LU0589944569.HKD","LU0532188223.SGD","LU2045819591.USD","RA","LU0261945553.USD","SG9999002679.SGD","LU0516422952.EUR","LU2177674079.SGD","LU2152927971.USD","SG9999002620.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642201544","title":"Astellas Wraps Up Real-World Safety Study on Smyraf, Clarifying RA Market Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2642201544","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642201544?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:31","pubTimestamp":1781109096,"startTime":"0","endTime":"0","summary":"Astellas Pharma ($ALPMF) announced an update on their ongoing clinical study. The Japan Post-Marketing Surveillance – Specified Drug Use-results Su...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/astellas-wraps-up-real-world-safety-study-on-smyraf-clarifying-ra-market-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/astellas-wraps-up-real-world-safety-study-on-smyraf-clarifying-ra-market-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442360","title":"Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442360","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642442360?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091000,"startTime":"0","endTime":"0","summary":"CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA mul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309602/0/en/Cullinan-Therapeutics-Shares-New-Clinical-Data-Across-Its-Portfolio-of-T-Cell-Engager-Programs-Targeting-CD19-and-BCMA-in-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","BK4077","LU0963586101.USD","IE00B7SZL793.SGD","SLE","BK4199","CGEM","IE0031619046.USD","BK4187","RA","IE00B66KJ199.SGD","ITP","BK4006","CRS","LU2065731478.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435973","title":"Brookfield Real Assets Income Fund names Oaktree’s Aaron Greenberg to run securitized credit allocation","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435973?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:20","pubTimestamp":1780939208,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund announced a portfolio manager change for its securitized credit allocation at sub-adviser Oaktree, effective June 30, 2026.Justin Guichard will step down from the role. Aaron Greenberg will take over.Greenberg is a managing director at Oaktree. He was named portfolio manager for Oaktree’s Real Estate Debt strategy, co-portfolio manager for Structured Credit.Greenberg previously worked as a CMBS trader at Morgan Stanley. He later led Deutsche Bank’s secondary trading desk.Co-portfolio managers Gaal Surugeon, Chris Janus, Riley O’Neil will remain responsible for day-to-day management and strategic allocation decisions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLbBM72w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD","NDAQ","SG9999014039.USD","BK4112","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU0314104364.USD","RA","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641484542","title":"Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2641484542","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641484542?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:31","pubTimestamp":1780921860,"startTime":"0","endTime":"0","summary":"First regulatory approval for Sjgren’s disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statist","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3308123/0/en/Telitacicept-Receives-NMPA-Approval-for-the-Treatment-of-Sj%C3%B6gren-s-Disease-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489805","title":"Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489805","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489805?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:00","pubTimestamp":1780916400,"startTime":"0","endTime":"0","summary":"KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307932/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Lupus-Data-for-KT-579-First-in-Class-Oral-IRF5-Degrader-at-EULAR-and-FOCIS-Congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SG9999004220.SGD","IBD","KT","LU0541502299.USD","BK4139","BK4115","KYMR","LU0541501648.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641450485","title":"Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2641450485","media":"GlobeNewswire","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641450485?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjgren disease and systemic sclerosi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307910/0/en/Artiva-Biotherapeutics-Highlights-AlloNK-Data-Presented-at-EULAR-2026-FDA-RMAT-Designation-in-Refractory-Rheumatoid-Arthritis-and-Webcast-Today.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0031619046.USD","RA","ARTV","IE00B66KJ199.SGD","BK4187","LABU","LU0963586101.USD","CRS","IE00B7SZL793.SGD","BK4588","LU2065731478.USD","BK4585","BK4006","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641179545","title":"Can IMVT-1402’s Phase 2 RA Data Reframe Immunovant’s (IMVT) Autoimmune Pipeline Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641179545","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641179545?lang=en_us&edition=fundamental","pubTime":"2026-06-08 01:13","pubTimestamp":1780852390,"startTime":"0","endTime":"0","summary":"Recent commentary on Immunovant’s IMVT-1402 program highlighted high response rates in a completed Phase 2 rheumatoid arthritis trial, including in patients who had already received multiple advanced therapies.\nThis focus on difficult-to-treat patients has pushed IMVT-1402 to the center of Immunovant’s story, raising questions about how such response rates could shape expectations for its broader autoimmune pipeline.\nWe’ll now look at how the strong IMVT-1402 Phase 2 responses in difficult...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/can-imvt-1402s-phase-2-ra-data-reframe-immunovants-imvt-auto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","RA","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641290111","title":"Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2641290111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641290111?lang=en_us&edition=fundamental","pubTime":"2026-06-06 17:15","pubTimestamp":1780737300,"startTime":"0","endTime":"0","summary":"Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/Cullinan-Therapeutics-Presents-Initial-Clinical-Data-for-CLN-978-a-CD19xCD3-T-Cell-Engager-at-the-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139","IE00B66KJ199.SGD","SLE","RA","BK4187","IE00B7SZL793.SGD","LU0963586101.USD","LU2065731478.USD","IE0031619046.USD","BK4006","CRS","BK4077","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640090118","title":"Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640090118","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640090118?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":"Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis (R","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305970/0/en/Spyre-Therapeutics-Announces-Completion-of-Enrollment-in-SKYWAY-Basket-Trial-Evaluating-SPY072-anti-TL1A-in-RA-PsA-and-axSpA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4162","BK4007","CIA","SYRE","LENZ","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640072973","title":"Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail","url":"https://stock-news.laohu8.com/highlight/detail?id=2640072973","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640072973?lang=en_us&edition=fundamental","pubTime":"2026-06-03 12:48","pubTimestamp":1780462082,"startTime":"0","endTime":"0","summary":"Pell Bio Med Technology  unit Peptide  Pharmaceutical Technology secured approval from China's National Medical Products Administration  to begin the Phase I clinical trial for its oral drug candidate PP011, according to a Tuesday Taiwan Exchange filing.The trial will be conducted in healthy subjects and targets rheumatoid arthritis , marking the first human study for the novel therapy.The company said the development program is planned through Phase two and Phase three trials before potential new drug application submission.Phase one completion is expected in the first quarter of 2027, it said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636685524","title":"Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2636685524","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636685524?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297380/0/en/Artiva-Biotherapeutics-Appoints-Veteran-Biotech-Executive-and-Drug-Developer-Diego-Miralles-M-D-as-President-and-Head-of-Research-and-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","ARTV","BK4139","RA","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636014880","title":"Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636014880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636014880?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  18, 2026  (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.(Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297050/0/en/Cullinan-Therapeutics-to-Present-Initial-Clinical-Data-for-CLN-978-in-Treatment-Refractory-Rheumatoid-Arthritis-and-Systemic-Lupus-Erythematosus-at-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4139","CGEM","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772596","title":"First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772596","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772596?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295401/0/en/First-Tracks-Biotherapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635814748","title":"Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2635814748","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635814748?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:10","pubTimestamp":1778764255,"startTime":"0","endTime":"0","summary":"Director Heather S. Goldman sold 2,750 shares of Brookfield Real Assets Income Fund common stock on May 13 at USD 12.72.Direct holdings fell to 21 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL8vLx3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Brookfield Real Assets director Heather S. Goldman disposes 2,750 shares for $34,980.84","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171647","title":"Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171647","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635171647?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":"Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294940/0/en/Vor-Bio-Announces-Publication-of-Interim-Analysis-of-TELIGAN-a-China-Phase-3-Trial-of-Telitacicept-in-IgA-Nephropathy-in-The-New-England-Journal-of-Medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782088","title":"Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782088?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initia","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4581","LU0949170772.SGD","FATE","LU0289960550.SGD","LU2506951875.HKD","LU2746668974.SGD","LU1894683348.USD","BK4504","LU0795875086.SGD","SLE","LU0098860793.USD","LU2133065610.SGD","LU0912757837.SGD","BK4139","LU0096364046.USD","LU1894683264.USD","LU1920062954.HKD","RA","SG9999014567.USD","SG9999011175.SGD","BK4080","LU2237443622.USD","LU2237443465.HKD","LU0882574139.USD","BK4559","IE00BVYPNW00.USD","LU1868837136.USD","KO","CMC","LU0170899867.USD","LU1868836591.USD","IE00B3PB1722.GBP","LU1732799900.SGD","IE00BLSP4239.USD","LU0545039389.USD","SG9999014559.SGD","LU2347655156.SGD","IE00BBT3K403.USD","IND","LU1670711123.USD","LU1221951046.USD","LU1920063259.USD","LU2125154935.USD","SITC","LU0971096721.USD","LU2125154778.USD","IIM","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782086","title":"Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782086","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782086?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of teli","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3294002/0/en/Vor-Bio-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","RA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}